A Study to Assess the Effect of Empasiprubart on Nerve Morphology by Ultrasound in Adults With Multifocal Motor Neuropathy

Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
Sponsorargenx

About this trial

The main purpose of the study is to evaluate empasiprubart use in adults living with Multifocal Motor Neuropathy (MMN). The researchers will evaluate the effect of empasiprubart on the thickness of the nerves, muscle strength, movement, and on the potential improvement of grip strength of the participants in handling objects.

The study consists of an open-label treatment period where all participants will receive empasiprubart intravenously (IV). After the last dose of empasiprubart participants will enter a safety follow-up period for up to 15 months.

The total study duration for each participant will be approximately 29 months.

More information can be found here: clinicaltrials.argenx.com/empasound

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Is at least 18 years old

Diagnosed with MMN

Has an MMN-RODS centile score of ≤90

Has confirmed nerve thickening in at least 1 nerve per ultrasound measurement

Disqualifiers

Besides the indication under study, known autoimmune disease or any medical condition that, in the investigator's opinion, would interfere with an accurate assessment of clinical symptoms of MMN or puts the participant at undue risk.

Trial design

Design model

Single group

Treatments tested in this trial

  • Empasiprubart IV

    Biological/Vaccine

    Intravenous infusions of empasiprubart

Treatment groups

60 Participants
are divided into 1 treatment group
Group A: Empasiprubart IVExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Change from baseline in nerve CSA at week 24 as measured by ultrasound imaging of the median nerve and brachial plexus (individual nerves and average sum score)

CSA : cross-sectional area

Time frame
Up to 48 weeks

Secondary outcomes

1

Change from baseline in GS in both hands over time

The grip strength (GS) will be measured using a vigorimeter

Time frame
Up to 48 weeks
2

Change from baseline in MMN-RODS over time

The MMN Rasch-Built Overall Disability Scale (MMN-RODS) is a disease-specific patient-reported outcome instrument that captures activity limitations in patients with MMN. The total raw score will be transformed to a centile score, ranging from 0 (worst outcome) to 100 (best outcome)

Time frame
Up to 48 weeks
3

Change from baseline in mMRC-14 sum score over time

The modified Medical Research Council (mMRC)-14 is a questionnaire where each muscle group is scored from 0 (paralysis) to 5 (normal strength). A higher value indicates better muscle strength. The total score is based on the sum of both the left and right side of the body

Time frame
Up to 48 weeks
4

Percentage change from baseline in time to complete the 9-HPT with both hands over time

The 9-Hole Peg Test (9-HPT) is a quantitative measure of upper extremity (arm and hand) function. Both the dominant and nondominant hands will be tested twice (2 consecutive trials of the dominant hand, followed immediately by 2 consecutive trials of the nondominant hand).

Time frame
Up to 48 weeks

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.